Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almitrine bismesylate for hypoxaemia in COVID-19
2020-002567-57Phase 4Unknown
- Sponsor
- University of Oxford
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of almitrine in coronavirus disease 2019 (COVID-19) and acute respiratory decompensation, sponsored by University of Oxford. Primary endpoint: Change in level of respiratory support over 7 days of treatment. Status: unknown.
02
Drugs
almitrine
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory decompensation
Beyond the preview
Go deeper on 2020-002567-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002567-57.